CMS Approves Coverage of COVID Antibody Treatment for Medicare Beneficiaries  

New COVID cases reported daily have more than doubled during recent weeks, since a more modest July surge.

As the nation’s COVID-19 pandemic continues to spiral out of control, federal authorities are racing to find ways to mitigate the spread.

The Centers for Medicare & Medicaid Services (CMS) announced last week that Medicare beneficiaries will be eligible to receive coverage of monoclonal antibodies to treat COVID, with no cost-sharing, during the duration of the current public health emergency (PHE). The coverage will apply to monoclonal antibody infusion of bamlanivimab, which received an emergency use authorization (EUA) from the U.S. Food and Drug Administration just days ago.

“Today, CMS is announcing a historic, first-of-its kind policy that drastically expands access to COVID-19 monoclonal antibodies to beneficiaries without cost-sharing,” CMS Administrator Seema Verma said in a statement. “Our timely approach means beneficiaries can receive these potentially lifesaving therapies in a range of settings – such as in a doctor’s office, nursing home, (or) infusion centers, as long as safety precautions can be met. This aggressive action and innovative approach will undoubtedly save lives.”

New COVID cases reported on a daily basis in the U.S. climbed to nearly 40,000 during an early-year surge affecting major metropolitan areas on both coasts, a figure that soared to 75,000 during a more widespread secondary surge occurring in July. But that metric has exploded during recent weeks, with a staggering record 184,000 new cases reported in the U.S. in one 24-hour period over the weekend.

As of the weekend, nearly 70,000 people nationwide were hospitalized with COVID – a figure greater than the capacity of more than half of NFL stadiums.

CMS in its announcement said it anticipates that the monoclonal antibody treatment will initially be given to healthcare providers at no charge, but it would cover any charges incurred going forward in other circumstances. When providers begin to purchase monoclonal antibody products, Medicare anticipates setting the payment rate in the same way it set the payment rates for COVID-19 vaccines – 95 percent of the average wholesale price for such vaccines in many provider settings, for example. This means that cases involving monoclonal antibody treatment will not be eligible for the enhanced payment established under the Medicare Inpatient Prospective Payment System (IPPS) in CMS-9912-IFC.

CMS added that it will issue billing and coding instructions for providers in the coming days.

“CMS anticipates the announcement today will allow for a broad range of providers and suppliers, including freestanding and hospital-based infusion centers, home health agencies, nursing homes, and entities with whom nursing homes contract, to administer this treatment in accordance with the EUA, and bill Medicare to administer these infusions,” the agency said in its announcement.

Under Section 6008 of the Families First Coronavirus Response Act (FFCRA), state and territorial Medicaid programs may receive a temporary 6.2 percentage point increase in the Federal Medical Assistance Percentage (FMAP), through the end of the quarter in which the COVID-19 PHE ends, officials added. A condition for receipt of this enhanced federal match is that a state or territory must cover COVID-19 testing services and treatments, including vaccines and their administration, specialized equipment, and therapies for Medicaid enrollees without cost-sharing. This means that this monoclonal antibody infusion is expected to be covered when furnished to Medicaid beneficiaries, in accordance with the EUA, during this period, with limited exceptions.

To view the CMS Monoclonal Antibody COVID-19 Infusion Program Instruction, go online to https://www.cms.gov/files/document/covid-medicare-monoclonal-antibody-infusion-program-instruction.pdf.

The global COVID-19 pandemic has sickened nearly 55 million people worldwide, killing an estimated 1.3 million. The United States accounts for approximately 11.2 million cases and 250,000 deaths alone.

Facebook
Twitter
LinkedIn

Mark Spivey

Mark Spivey is a national correspondent for RACmonitor.com, ICD10monitor.com, and Auditor Monitor who has been writing and editing material about the federal oversight of American healthcare for more than a decade.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

2026 IPPS Masterclass 3: Master MS-DRG Shifts and NTAPs

2026 IPPS Masterclass Day 3: MS-DRG Shifts and NTAPs

This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 14, 2025
2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 13, 2025
2026 IPPS Masterclass 1: Master ICD-10-CM Changes

2026 IPPS Masterclass Day 1: Master ICD-10-CM Changes

This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 12, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24